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Abstract
Background: Women have a reduced risk of developing Parkinson's disease (PD) compared with age-matched men. 
Neuro-protective effects of estrogen potentially explain this difference. Tamoxifen, commonly used in breast cancer 
treatment, may interfere with the protective effects of estrogen and increase risk of PD. We compared the rate of PD in 
Danish breast cancer patients treated with tamoxifen to the rate among those not treated with tamoxifen.
Methods: A cohort of 15,419 breast cancer patients identified from the Danish Breast Cancer Collaborative Group 
database was linked to the National Registry of Patients to identify PD diagnoses. Overall risk and rate of PD following 
identification into the study was compared between patients treated with tamoxifen as adjuvant hormonal therapy 
and patients not receiving tamoxifen. Time-dependent effects of tamoxifen treatment on PD rate were examined to 
estimate the likely induction period for tamoxifen.
Results: In total, 35 cases of PD were identified among the 15,419 breast cancer patients. No overall effect of tamoxifen 
on rate of PD was observed (HR = 1.3, 95% CI: 0.64-2.5), but a PD hazard ratio of 5.1 (95% CI: 1.0-25) was seen four to six 
years following initiation of tamoxifen treatment.
Conclusions: These results provide evidence that the neuro-protective properties of estrogen against PD occurrence 
may be disrupted by tamoxifen therapy. Tamoxifen treatments may be associated with an increased rate of PD; 
however these effects act after four years, are of limited duration, and the adverse effect is overwhelmed by the 
protection against breast recurrence conferred by tamoxifen therapy.
Background
Parkinson's disease (PD) is a degenerative movement dis-
order usually occurring late in life. It is the second most
common neurodegenerative disease after Alzheimer dis-
ease (AD) and has a prevalence of approximately 1.8%
among people over the age of 65 [1,2]. Women have a
reduced risk of Parkinson's disease compared to age-
matched men [1]. This rate difference, combined with
evidence of neuro-protective properties of estrogen in
AD, and probably also in other neurodegenerative disor-
ders [3], has prompted studies of estrogen's effect on PD
risk and treatment. Improved motor function has been
associated with estrogen treatment in studies of women
with PD [4-6]. Furthermore, studies have shown some
factors associated with estrogen, such as hormone
replacement therapy [7], length of fertile life [8], or
receipt of hysterectomy [9] are also associated with PD
risk. Other studies however, have shown no or an inverse
association with the same or similar factors [8-12]. Selec-
tive estrogen receptor modulators (SERMs) are a class of
pharmaceuticals that can act as both estrogens and anti-
estrogens in different tissues [13]. Tamoxifen was the first
SERM developed, and the observed anti-estrogenic prop-
erties led to its use in treatment of breast cancer [13,14].
Tamoxifen decreases mortality and recurrence rates in
breast cancer patients, and prevents breast cancer occur-
rence in high-risk women [15,16]. Tamoxifen is most
effective in treating and preventing the approximately
70% of breast cancer tumors that express ESR1 (the gene
encoding the Estrogen Receptor-α protein), classified as
estrogen receptor positive (ER+) tumors [15,17].
The mechanisms by which SERMs act are not com-
pletely clear, however it is known that SERMs bind to the
estrogen receptors (ERs) and form ER complexes similar
to the estrogen receptor-estrogens complexes. These
complexes can then either promote gene transcription,
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transcription, or become misfolded and promote a differ-
ent set of gene transcription [13,14].
As tamoxifen has become widely used for treatment
and prevention of breast cancer [15,18], interest in the
effects of SERMs on the brain has grown. It is not clear
whether tamoxifen acts as an estrogen or anti-estrogen in
the brain, although animal studies of serotonin transport
suggest that SERMs can act as an antagonist to estrogen
in at least some parts of the brain [19,20]. Studies of the
relation between SERM treatment and PD have mainly
focused on animal models of PD induction, in particular
PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) or methamphetamine (MA) in mouse
models.
In these studies, estrogen decreases the toxic effects of
MPTP in male and female mice, but simultaneous admin-
istration of tamoxifen blocks the protective effect of
estrogen against MPTP induced PD [21-24]. In addition,
MPTP-treated and MA-treated mice, when administered
tamoxifen and estrogen together, have significantly
reduced dopamine levels compared with mice adminis-
tered estrogen alone. This result suggests an anti-estro-
genic effect of tamoxifen on the dopaminergic neurons
affected in PD [24,25]. These animal studies indicate that
tamoxifen may oppose the neuro-protective benefits of
estrogen in the brain, particularly in the parts of the brain
affected by PD. Nevertheless, no epidemiologic studies of
the association between tamoxifen treatment and PD
occurrence have been conducted.
In this study, we have identified a cohort of breast can-
cer patients registered by the Danish Breast Cancer Col-
laborative Group (DBCG) database and linked the cohort
to the National Registry of Patients covering all Danish
hospitals. We compared the rates of Parkinson's disease
diagnosis between those patients whose treatment




An initial cohort of 15,440 women between the ages of 45
and 70 years, diagnosed with stage I or II, estrogen recep-
tor positive (ER+) breast cancer between 1990 and 2004
were identified from the Danish Breast Cancer Collabor-
ative Group (DBCG). The DBCG was created in 1977 to
ensure comprehensive diagnosis, treatment, and study of
breast cancer in Denmark [26] and maintains detailed
information about nationwide breast cancer diagnoses,
outcomes, and treatments, including tamoxifen treat-
ment. The Danish national health care system enables
linkage of the breast cancer patient cohorts to the Danish
National Registry of Patients to ascertain subsequent PD
diagnosis. Tamoxifen treatment is only indicated in ER+
breast cancer and few ER- cases are treated with tamox-
ifen. A relationship between ER status and risk of PD,
possibly mediated by cumulative estrogen exposure [27],
may also exist. Therefore to avoid confounding by ER sta-
tus, only women with ER+ breast cancer were included in
this study.
Use of tamoxifen was determined from the assigned
treatment protocol for each patient collected from the
DBCG database [28]. Tamoxifen exposure was defined
for this study by the assigned treatment protocol for each
patient to reduce confounding by non-compliance and
other factors. Determination of treatment protocols was
dependent on the risk profile of the patient, which was
determined mainly by the cancer stage. Patients defined
as low-risk (generally stage I patients, with smaller
tumors that had not metastasized locally) were not sys-
tematically assigned therapy through the DBCG, but
were treated at the discretion of their physicians [29].
High-risk patients included in this study (stage II with
larger tumors or tumors that had metastasized locally)
were recommended standardized treatment based on
menopausal status and estrogen receptor status. In addi-
tion, some patients in the high-risk group were random-
ized to one of several clinical trials [29]. Because the
women with stage II cancer were subject to standardized
treatment protocols, there is less potential for confound-
ing by unmeasured variables (such as smoking) in this
group.
Follow-up time was measured as the interval from the
date of breast cancer surgery, when treatment protocols
were assigned, to the date of first diagnosis of PD or to
censoring due to death, emigration, or the end of the
study period (12/31/2005). To reduce misclassification of
the PD outcome, follow-up time was also censored at the
time of a diagnosis of brain metastasis, because symp-
toms of brain metastasis could be misinterpreted as PD
onset. To identify the date of initial hospital diagnosis of
PD, the Central Population Register (CPR) identification
number assigned to all Danish citizens was used to query
the Danish National Registry of Patients (NRP). The NRP
records all outpatient visits after 1994 and all hospital
admissions after 1977 and includes the date of the spe-
cialist visit or hospital discharge, and codes (based on
International Classification of Disease version 8 or 10
codes) for up to 20 different disease diagnoses identified
as related to the visit by the health care provider [30]. The
date of initial diagnosis of PD is therefore the first date of
any visit or discharge associated with one of the Interna-
tional Classification of Disease codes for PD (ICD8 342.0
or ICD10 G20[31]) in the National Registry of Patients.
Eighteen women with PD diagnostic codes identified
before breast cancer diagnosis were excluded from the
study. In addition, two patients diagnosed with both PD
and brain cancer and one patient diagnosed with brain
cancer before breast cancer diagnosis were excluded from
the study to avoid potential misclassification of the PD
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15,440 to a final cohort of 15,419 patients.
This study was approved by the Danish Registry Board.
There is no requirement for registry research of this sort
to be further approved by an ethics board in Denmark.
Statistical Analyses
We computed the crude incidence rate of PD for women
from the study cohort assigned to tamoxifen treatment
(N = 7153) and compared it with the rate among women
from the study cohort who were not assigned tamoxifen
treatment (N = 8266). We used proportional hazard
regression implemented in SAS version 9 to calculate a
hazard ratio associating tamoxifen exposure with PD
incidence. Potential confounding by age of breast cancer
diagnosis, date of treatment assignment, and breast can-
cer stage was assessed by determining the association
between potential confounders and the disease in the
unexposed group (tamoxifen untreated), and by compar-
ing the change in estimates of the association between
tamoxifen and PD occurrence when controlling for
potential confounding variables. Age and calendar time
of cancer diagnosis and treatment were found to be asso-
ciated with, and were found to modify, the effect of
tamoxifen treatment rate of PD. The hazard ratio was
therefore also calculated adjusting for age at breast cancer
diagnosis and date of treatment assignment. In addition,
analyses were performed in only high-risk patients (stage
II), who were subject to standardized treatment proto-
cols, to reduce confounding by unmeasured variables
(such as smoking).
Because the potential induction time between tamox-
ifen exposure and onset of PD is uncertain, PD-free sur-
vival curves and log-log survival plots were generated
using the Lifetest procedure in SAS to examine the valid-
ity of the proportional hazards assumption. We expected
that there would be an induction time immediately fol-
lowing the start of tamoxifen treatment, during which the
drug would not have had an opportunity to have a phar-
macologic effect on PD occurrence. Similarly, we
expected that there would be a point in time after treat-
ment was completed by which it would no longer affect
PD risk. To assess these induction period effects on PD
rate, we repeated the proportional hazards regression
within strata of the estimated periods before, during, and
after which the tamoxifen treatment may have had an
effect on PD occurrence. The boundaries of these periods
were determined empirically by examination of the PD-
free survival curves and log-log survival plots.
Results
In the final cohort of 15,419 ER+ breast cancer patients,
7153 patients were assigned to tamoxifen treatment pro-
tocols and 8266 were not. Descriptive statistics including
age, cancer stage, and assigned tamoxifen treatment
duration are described in Table 1. In total, 35 cases of PD
were identified; 15 in the tamoxifen treated cohort and 20
in the cohort not treated with tamoxifen. The unadjusted
hazard ratio was 1.7 (95% CI of 0.83-3.3). Adjustment for
age at breast cancer diagnosis and date of treatment
assignment reduced the hazard ratio to 1.3 (95% CI 0.64-
2.5). Analyses restricted to advanced stage cases, thus
excluding stage I cases who were not subject to system-
atic treatment recommendations, showed a similar asso-
ciation, with an age and date adjusted hazard ratio of 1.3
(95% CI 0.47-3.5).
Figure 1 shows the PD-free survival curves with confi-
dence intervals for the tamoxifen treated and untreated
groups. The confidence intervals overlap at all time peri-
ods (shown by the dark grey shading), indicating no sig-
nificant overall difference in survival between the groups.
Nevertheless, the shapes of the curves indicate a violation
of the proportional hazards assumption approximately
four to six years after breast cancer diagnosis (approxi-
mately the time of tamoxifen inception). Instead of dis-
playing the steadily increasing gap expected under
proportional hazards, the survival curves start close to
one another, diverge quickly between years four and six,
and then maintain a near uniform distance. This pattern
indicates a time-dependent effect of tamoxifen treatment
on PD occurrence.
The results of three independent proportional hazard
regression models representing the periods before, dur-
ing, and after this presumed window of effect of tamox-
ifen treatment on PD are shown in Table 2. The period
four to six years after beginning treatment is associated
with a hazard ratio of 5.1 (95% CI 1.02 to 25), while expo-
sure before and after that range shows little effect on PD
hazard.
Discussion
An examination of the effect of tamoxifen treatment on
PD rate among 15,419 female breast cancer cases in the
Danish Breast Cancer Collaborative group did not show a
significant difference in rate of PD overall. Our results do,
however, suggest a time-dependent effect starting around
four years after inception of tamoxifen therapy, which
was born out in stratified hazard analyses. Estimated haz-
ard ratios over the first three years after beginning
tamoxifen treatment and more than six years after begin-
ning treatment showed little or no effect of tamoxifen on
the rate of PD. In the range of 4 to 6 years, however, an
increase in the hazard ratio was observed. This pattern of
time-varying effect is consistent with the theory that cer-
tain exposures will only show an effect within a limited
time frame, long enough after exposure for the effect to
become apparent, but which ceases when the exposure is
no longer active. While the evidence for an effect of
Latourelle et al. BMC Neurology 2010, 10:23
http://www.biomedcentral.com/1471-2377/10/23
Page 4 of 7tamoxifen treatment on PD risk is equivocal, this effect
suggests that treatment may hasten the occurrence of PD
pathology or symptoms. This result is also consistent
with the hypothesis and animal-model evidence that
estrogen has a neuro-protective effect that functions
through a mechanism that can be disrupted by tamoxifen,
likely through estrogen receptors.
The animal-model studies have not investigated time-
dependent effects of tamoxifen in the brain. Clinical trials
of differing durations of tamoxifen treatment for breast
cancer show that a 5 year duration of tamoxifen treat-
ment is more effective than shorter treatments [32], con-
sistent with the view that tamoxifen treatment does not
induce a permanent biological effect, but rather a time-
limited effect that eventually wanes. Interestingly, a study
of potential carryover effects of tamoxifen in the Early
Breast Cancer Trialists' Collaborative Group (EBCTCG)
suggests that the majority of tamoxifen's benefit in reduc-
ing recurrence risk occurred within the first five years
after initiating treatment and no additional benefit was
detected after six years [33], consistent with the endpoint
of effect on hazard of PD in this study. The induction
period of four years seen in this study is not consistent
with the effects of tamoxifen seen in breast cancer trials,
though the pre-clinical progression and latency period of
PD is not well understood [34], making it difficult to
speculate on an appropriate induction period.
The major strength of this study is that the DBCG and
the Danish National Registry of Patients provide a large
well-characterized nationwide cohort of breast cancer
cases for study. Such a large cohort of tamoxifen-treated
breast cancer patients with the ability to assess neurologi-
cal outcomes is very rare. Despite the large cohort, how-
ever, only a limited number of PD cases were identified.
Table 1: The age distribution, cancer stage, and assigned treatment protocols for 15,419 female ER+ breast cancer 
patients
All Tamoxifen exposed Tamoxifen
unexposed
All ER+ women 15419 7153 8266
Age-range
45-50 3377 1129 2248
51-55 3127 1536 1591
56-60 3317 1695 1622
61-65 3229 1649 1580
66-70 2369 1144 1225
Stage of cancer
1 6823 907 5916
2 8596 6246 2350
Assigned tamoxifen 
treatment duration
180 days 354 354
365 days 990 990
730 days 620 620
1825 days 5039 5039
none 8266 8266
missing 150 150
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The age-specific incidence rates of PD in these women
(15.6/100,000 person-years for ages 50-64, 58.6/100,000
person-years for ages 65-79) are similar to the rates in the
general population of women in Denmark (9.4/100,000
person-years for ages 50-64, 57.6/100,000 person-years
for ages 65-79)[31]A second limitation is the possibility
for uncontrolled confounding by smoking history or caf-
feine use. Former smoking has been consistently shown
to reduce the rate of PD occurrence [35,36], and caffeine
use may also be associated with a decreased risk of the
disease particularly in women [11,12,37], but neither
smoking nor caffeine information was available for mem-
bers of this cohort. Cigarette smoking is common in
women in Denmark, with a prevalence of 45% in women
age 35 to 64 compared with a median of 24% in other
European countries [38,39]. Smoking is at most a weak
risk factor for breast cancer, but as the study only
included breast cancer patients, of greater concern is
whether smoking may be associated with receipt of
tamoxifen therapy among breast cancer patient. (In per-
sonal communications, Danish oncologists report that
smoking status would not be a factor considered in pre-
scribing tamoxifen treatment for breast cancer.) Never-
theless, studies have shown an increased risk of
tamoxifen related side effects in smokers [40] and it may
be possible for some physicians concerned about tamox-
ifen related side effects to be less likely to prescribe
tamoxifen treatment to smokers. If more non-smokers, at
higher risk of PD, were exposed to tamoxifen, uncon-
trolled confounding could potentially influence the
results seen in this study. It is unlikely that this confound-
ing would have a strong effect only in the range of four to
six years after initiation of tamoxifen therapy, during
which the strongest effect was seen in this study, but it
could influence the overall increased rate of PD seen in
the tamoxifen exposed group.
To assess the potential bias due to uncontrolled con-
founding by smoking, we conducted a quantitative bias
analysis [41]. We used a previously estimated relative rate
of PD of 0.7 comparing smokers with nonsmokers [42]
and an estimated OR of 1.5 for the association between
smoking and tamoxifen treatment. This OR assumes
smokers were two-thirds as likely to receive tamoxifen
treatment as non-smokers, all other factors held con-
stant. With these assumptions, the adjusted hazard ratio
of PD associated with tamoxifen treatment would
decrease only slightly from 1.7 to 1.3. Even with an
implausibly strong association between smoking and
receipt of tamoxifen treatment (OR = 5), external adjust-
ment for smoking does not completely remove the posi-
tive association between PD and tamoxifen (predicted RR
of 1.20).
A third limitation is the potential for some misclassifi-
cation of PD and time of PD diagnosis ascertained
through the codes in the Danish National Registry of
Patients. A validation study conducted within the Regis-
try of Patients compared diagnoses in medical records to
the registry codes and estimated a false-positive rate of
PD diagnosis between 6% and 20% [43] in the registry. No
examination of the false-negative rate was performed in
this study, but as PD is a rare disease, virtually all people
classified as non-PD are likely to be truly non-PD. The
criteria used for defining PD from the medical records in
the validation study was not specifically explained, so it is
uncertain if this validation corresponds to commonly-
Figure 1 PD-Free Survival Curves. The PD-free Survival curves and 
confidence intervals for tamoxifen treated and untreated are shown. 
Dark grey shading indicates where the confidence intervals overlap.







Hazard Ratio Lower 95% CI Upper 95% CI p-value
0-4 years 11 (5) 0.89 0.26 3.0 0.84
4-6 years 8 (6) 5.1 1.02 25 0.047
6+ years 16 (4) 0.79 0.25 2. 5 0.68
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criteria [44]). A study of the purchase of anti-parkin-
sonism drugs (APD) using the Danish Medicinal Product
Statistics database suggests that the incident rate of APD
purchases is twice as high (43.4/100,000 person-years)
[45] as the incident rate of PD (19.9/100,000 person-
years) estimated from the National Registry of Patients
[31]. This study did not match APD drug purchase to dis-
ease diagnoses or drug indication, thus the discrepancy
may be due to the use of APD for clinical purposes other
than PD treatment, but may also indicate an underreport-
ing of PD in the National Registry of Patients [45]. It is
unlikely that misclassification of PD status would occur at
different rates between breast cancer patients treated or
not treated with tamoxifen, and thus we expect PD mis-
classification would bias the estimated associations
toward the null.
Conclusions
These findings are based on a very small number of PD
cases, as PD remains a rare disease, particularly among
women. In addition, the determination of the time-frame
of potential effect was determined empirically from study
data. Only six exposed cases of PD were diagnosed dur-
ing the period of potential effect four to six years after
breast cancer diagnosis. While this frequency is greater
than expected, caution should be used in interpreting
these results due to the small number of observed cases
and empirical delineation of the induction period. Ideally,
these findings would spur efforts at replication in another
cohort. It is also important to remember that while the
hazard ratio of 5.1 represents a large relative effect, the
absolute increased rate of PD is negligible when com-
pared to the benefits of tamoxifen in preventing breast
cancer recurrences. The main value of this study's result,
therefore, is its contribution to understanding a potential
underlying disease mechanism in PD and particularly the
effect of estrogen on the disease process.
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